Recent Patents and Commercially Available Nanotherapeutics on Hepatocellular Carcinoma
- Authors: Susanthi Jayasinghe1, Imalka Munaweera2, Disni Dedunupitiya3, Chamalki Madhusha4, Nilwala Kottegoda5, Veranja Karunaratne6
-
View Affiliations Hide Affiliations1 Department of Chemistry, Faculty of Science, University of Peradeniya, Peradeniya, Sri Lanka 2 Department of Chemistry, Faculty of Applied Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka ⋅ Instrument Center, Faculty of Applied Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka 3 Department of Chemistry, Faculty of Science, University of Peradeniya, Peradeniya, Sri Lanka 4 Department of Chemistry, Faculty of Applied Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka 5 Department of Chemistry, Faculty of Applied Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka ⋅ Center for Advanced Materials Research (CAMR), Faculty of Applied Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka 6 Department of Chemistry, Faculty of Science, University of Peradeniya, Peradeniya, Sri Lanka
- Source: Nanotherapeutics for the Treatment of Hepatocellular Carcinoma , pp 449-489
- Publication Date: March 2022
- Language: English
Recent Patents and Commercially Available Nanotherapeutics on Hepatocellular Carcinoma, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789815039740/chapter-11-1.gif
Hepatocellular carcinoma (HCC) remains a significant reason for cancerassociateddeaths. The diagnostic methods for early-stage detection are insufficient,and there are limited treatments available for the late stages. Thus, novel approachesfrom nanotechnology have gained much attention to overcome the major hurdles indesigning nanoscale materials that could be used in both diagnosis and treatments.Recently approved patents showed that progress had been made with nanotechnologyin both diagnosis and therapy. The invention of HCC biomarkers, such as alphafetoprotein,liver carboxylesterase 1, glypican-3, endoglin, or CD105, has madesignificant progress in the area of diagnosis. On the other hand, methods for enhancingthe sensitivity and specificity of imaging in nuclear magnetic resonance using Ga3+ andnanogold Computed Tomography (CT) contrast agents are noteworthy in the accuracyof cancer imaging. Nanodrugs have long-circulating times inside the body whileenhancing the bioavailability of these drugs and improving efficacy without higherdoses. Polymer-based nanoparticles, liposomal nanoparticles, and magnetic nano-drugvehicles are used in therapeutics to transport drugs like paclitaxel, docetaxel,doxorubicin, and mitomycin. Antisense oligodeoxynucleotides of midkine, phosphorylN-fatty acyl nucleosides, siRNAs, and polypeptides have all been used. The longperiod between clinical trials and commercialization of nanotherapeutics and key issuesrelated to clinical development should be addressed by eliminating the regulatoryhurdles limiting nanotherapeutics for HCC in the market.
-
From This Site
/content/books/9789815039740.chapter-11dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
